Irish drug company Alkermes says results of an early-stage trial of its reformulated version of Biogen Idec's blockbuster multiple sclerosis pill show it may have fewer side effects, and has potential to be taken once a day instead of twice. Alkermes , which has a significant research facility in Waltham, said the Phase 1 trial of 104 healthy people compared its reformulation of the active ingredient in Tecfidera, which it calls ALKS 8700, to both the original and a placebo.